{"filings":[{"id":536517,"accession_number":"0001493152-26-024517","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2026-05-20T12:00:35+00:00","items":["7.01","9.01"],"status":"ready","headline":"Telomir Pharma reports peer-reviewed Telomir-Zn data showing survival benefit in Wilson's disease model","event_type":"other_material","confidence":"high","bullets":["Telomir-Zn dose-dependently improved survival, reduced hepatic copper burden and liver injury biomarkers (ALT, AST, bilirubin) in zebrafish Wilson's disease model.","Preclinical study published in Advances in Redox Research; demonstrates reductions in oxidative stress, ROS-Ca²⁺ amplification, and tissue degeneration.","First peer-reviewed publication for Telomir-Zn in Wilson's disease; supports mechanism across copper-redox modulation and mitochondrial protection.","Telomir-Zn already has FDA IND clearance for Phase 1/2 in Triple-Negative Breast Cancer (April 2026); new data further validates platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96995,"accession_number":"0001493152-26-019773","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA clears IND for Telomir-Zn in advanced triple-negative breast cancer; Phase 1/2 trial planned for 1H 2026","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for lead candidate Telomir-Zn in advanced/metastatic triple-negative breast cancer.","Phase 1/2 trial to enroll ~76 patients; Phase 1 dose-escalation, Phase 2 primary endpoint ORR.","Planned initiation in first half of 2026 at a leading US academic medical center.","Preclinical data included pharmacology, toxicology, PK, and biomarker analyses.","Translational biomarker program to assess epigenetic modulation and telomere dynamics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96994,"accession_number":"0001493152-26-018867","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","2.01","3.02","9.01"],"status":"ready","headline":"Telomir Pharmaceuticals completes acquisition of TELI, consolidating global rights to Telomir-1","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of TELI for 34,389,710 restricted shares of Telomir common stock to former TELI shareholders.","Bayshore Trust contributed $1 million at closing and has an option to provide up to $4 million upon IND acceptance and Phase 1/2 study start.","Option includes $2 million for 1,492,537 shares at $1.34 per share upon FDA IND acceptance, and another $2 million for the same number of shares upon Phase 1/2 initiation.","Transaction eliminates prior geographic fragmentation, giving Telomir full worldwide control of Telomir-1 development and commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111426,"accession_number":"0001493152-26-013872","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir regains Nasdaq compliance on annual meeting requirement","event_type":"regulatory","confidence":"high","bullets":["Received letter from Nasdaq on March 30, 2026 confirming compliance with Rule 5620(a).","Compliance achieved after holding the 2025 Annual Meeting of Shareholders.","Nasdaq has determined the matter closed.","No further actions required from the company regarding this deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111425,"accession_number":"0001493152-26-013785","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in metastatic triple-negative breast cancer","event_type":"regulatory","confidence":"high","bullets":["IND submitted March 31, 2026 for oral Telomir-Zn (Telomir-1) in advanced/metastatic TNBC.","Data from IND-enabling pharmacology, toxicology, and manufacturing studies included in submission.","Planned Phase 1/2 trial: 3+3 dose-escalation, then Simon two-stage with ORR as primary endpoint.","Preclinical GLP safety studies showed no treatment-related adverse or dose-limiting toxicities.","Telomir-1 reduces redox-active iron and increases zinc, inhibiting iron-dependent histone demethylases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111424,"accession_number":"0001493152-26-013240","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"TELO shareholders approve acquisition of Teli Pharma and increase share reserve to 11.5M","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Teli Pharmaceuticals approved; issuance of >20% new shares authorized.","2023 Omnibus Incentive Plan amended: share reserve increased from 6.5M to 11.5M shares and repricing allowed.","Bylaws amended to reduce quorum requirement to one-third of outstanding shares.","Directors elected: Erez Aminov, Matthew Whalen, Edward MacPherson, Matthew Del Giudice.","Ratification of Salberg & Company as independent auditor for FY 2025 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111423,"accession_number":"0001493152-26-006937","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir reports Telomir-1 induces near-complete tumor cell death in TNBC models; iron-rescue confirms mechanism","event_type":"other_material","confidence":"high","bullets":["Near-complete tumor cell mortality in MDA-MB-468 (Basal-A/EGFR-high) TNBC cells at 72h.","Significant partial reduction in HCC70 (Basal-like) and MDA-MB-231 (Claudin-low) cells.","Supplemental iron attenuated Telomir-Zn-induced mortality, supporting iron-dependent mechanism.","Prior zebrafish xenograft showed reduced growth/metastasis; IND submission expected Q1 2026.","GLP safety studies in rats/dogs showed no adverse toxicity; IND-enabling activities ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111422,"accession_number":"0001493152-26-005199","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharmaceuticals Reports Preclinical Data on Telomir-Zn Modulating Metal Balance","event_type":"other_material","confidence":"high","bullets":["Telomir-Zn induced rapid intracellular zinc increase and labile ferrous iron reduction within 30 minutes in preclinical studies.","Coordinated metal redistribution observed without loss of cell confluence or viability, supporting a non-cytotoxic mechanism.","Findings implicate epigenetic modulation, oxidative stress reduction, and mitochondrial stabilization in cancer and aging models.","Company advancing IND-enabling activities with planned IND submission in Q1 2026.","Manuscript submissions initiated for peer-reviewed journals based on completed studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111421,"accession_number":"0001493152-26-001170","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Telomir receives Nasdaq non-compliance notice for missing annual meeting; has until Feb 23 to submit plan","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Jan 8, 2026 for failure to hold annual meeting within 12 months of fiscal year end (Rule 5620(a)).","No immediate delisting; trading continues. Must submit compliance plan by Feb 23, 2026.","Preliminary proxy filed Nov 20, 2025 still under SEC review; expects to hold meeting promptly after clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111420,"accession_number":"0001493152-26-000267","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir-1 reduces tumor growth and metastases in aggressive TNBC models in preclinical study","event_type":"other_material","confidence":"high","bullets":["Telomir-1 showed statistically significant reductions in primary tumor growth in two of three aggressive TNBC zebrafish xenograft models.","In a paclitaxel-resistant model, Telomir-1 reduced tumor growth as monotherapy and in combination, and cut cancer cell spread.","Third model (broadly treatment-resistant, ~15-25% of TNBC) showed no significant effect from Telomir-1 or paclitaxel.","Responsive models represent ~40-60% of TNBC; company plans patient selection based on tumor biology for future trials.","Study used BioReperia’s ZTX ONCOLEADS platform; company continues IND-enabling activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128033,"accession_number":"0001493152-25-028620","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Telomir Pharmaceuticals Approves CEO Compensation Adjustments Including Incentive Payouts and Salary Increase","event_type":"leadership","confidence":"high","bullets":["CEO Erez Aminov received a 2025 short-term incentive payout of $400,000 for operational and financing achievements.","Contingent milestone payout of $150,000 approved for future FDA acceptance of the Telomir-1 IND submission.","Transaction advisory award of 3% of the total TELI acquisition value granted for leadership in negotiating the potential acquisition.","Base salary adjusted to $500,000 effective January 1, 2026, based on external benchmarking."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128032,"accession_number":"0001493152-25-028126","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharmaceuticals reports favorable GLP safety results for Telomir-1; IND submission targeted Q1 2026","event_type":"other_material","confidence":"high","bullets":["No treatment-related adverse or dose-limiting toxicities observed across cardiovascular, respiratory, phototoxicity, and repeat-dose safety studies in rats and dogs.","Telomir-1 well tolerated with consistent systemic exposure; no changes in blood pressure, heart rate, ECG, or body temperature in dogs.","Final quality assurance review ongoing; no findings preclude advancement into first-in-human studies.","Ongoing preclinical studies in triple-negative breast cancer and other age-related diseases; targeting IND submission Q1 2026 and first-in-human H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128031,"accession_number":"0001493152-25-024818","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharma reports Telomir-1 reduces PSA in prostate cancer cells in dose-related manner","event_type":"other_material","confidence":"high","bullets":["Telomir-1 reduced PSA levels in dose-related manner in androgen-responsive human prostate cancer cells (LNCaP) in vitro.","Also associated with reductions in cellular energy metabolism and viability in the same study.","In prior PC3 xenograft mouse model, Telomir-1 reduced tumor volume as single agent; full reduction with paclitaxel combo without mortality.","Paclitaxel alone achieved full tumor reduction but had high mortality; Telomir-1 combo showed no treatment-related deaths.","Company advancing IND-enabling activities for planned IND submission across oncology and aging-related conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128030,"accession_number":"0001493152-25-024491","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Telomir Pharmaceuticals director Craig Eagle resigns from board, effective Nov 14, 2025","event_type":"leadership","confidence":"high","bullets":["Craig Eagle resigned from the Board of Directors on November 14, 2025, effective immediately.","Resignation was not due to any disagreement with the Company, management, or other board members.","The Board thanked Mr. Eagle for his service; no successor has been announced.","Resignation letter attached as Exhibit 17.1 to the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128029,"accession_number":"0001493152-25-024450","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-11-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir-1 kills aggressive human leukemia cells in vitro; expands oncology profile into blood cancers","event_type":"other_material","confidence":"high","bullets":["Telomir-1 produced dose-dependent reduction in viability of human HL60 leukemia cells (aggressive AML model).","Leukemia cells depend on intracellular iron; Telomir-1 lowers intracellular Fe²⁺ more potently than DFO.","Prior research shows Telomir-1 reduces abnormal DNA methylation of tumor-suppressor genes and inhibits KDM histone demethylases.","Findings add to previously reported activity against triple-negative breast, pancreatic, and prostate cancer models."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128028,"accession_number":"0001493152-25-021712","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir-1 outperforms FDA-approved DFO in reducing intracellular iron in preclinical study","event_type":"other_material","confidence":"high","bullets":["Telomir-1 reduced intracellular Fe²⁺ in human keratinocytes in dose- and time-dependent manner at low-micromolar concentrations.","Deferoxamine (DFO) exhibited limited intracellular activity under equivalent conditions.","Telomir-1 formulated with zinc (Telomir-Zn) enables controlled exchange of metal ions – binding excess iron/copper while contributing zinc.","Findings support research into metal-ion balance, oxidative stress, and epigenetic enzyme dynamics in aging and disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128027,"accession_number":"0001493152-25-018907","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir-1 reduces DNA methylation of CASP8 and GSTP1 in aggressive prostate cancer model","event_type":"other_material","confidence":"medium","bullets":["Telomir-1 decreased DNA methylation of CASP8 (apoptosis) and GSTP1 (detoxification) genes at Day 21, vs vehicle and chemo.","Combination of Telomir-1 and chemo showed lower methylation than chemo alone, suggesting potentiation of epigenetic effects.","Rapamycin showed initial methylation reduction at Day 10 but rebounded by Day 21; Telomir-1 showed sustained progressive decrease.","Data derived from mice bearing human aggressive prostate tumors; preclinical, not yet in humans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128026,"accession_number":"0001493152-25-018634","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Telomir signs binding LOI to acquire TELI, consolidating worldwide rights to Telomir-1","event_type":"m_and_a","confidence":"high","bullets":["Acquires all TELI shares via stock-for-stock exchange; exchange ratio based on third-party valuation.","Certain TELI shareholders to contribute $5M cash: $1M at closing, $2M on FDA IND acceptance, $2M on Phase 1/2 start.","Transaction consolidates global IP rights to Telomir-1, an oral epigenetic therapy for cancer and aging.","No TELI leadership retained post-closing; TELI shareholders subject to six-month lock-up.","Closing subject to due diligence, board/stockholder approvals, regulatory clearances within 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128025,"accession_number":"0001493152-25-017916","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharma reports Telomir-1 kills pancreatic cancer cells in vitro; plans further studies","event_type":"other_material","confidence":"high","bullets":["Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in concentration-dependent manner.","Effects partially reversed by iron re-addition, suggesting iron-dependent processes contribute to response.","Telomir-1 previously shown to influence tumor suppressor genes and iron-dependent histone demethylases relevant to pancreatic cancer.","Pancreatic cancer has five-year survival rate of ~12%; current treatments limited by toxicity and resistance.","Telomir plans to expand preclinical research to leukemia models and initiate in vivo validation studies for IND preparation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128024,"accession_number":"0001493152-25-017422","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir-1 selectively kills triple-negative breast cancer cells in lab studies","event_type":"other_material","confidence":"high","bullets":["Telomir-1 produced concentration-dependent reduction in TNBC cell survival; iron addition reversed effect, confirming iron-dependent mechanism.","Compound targets aggressive TNBC cells' metabolic reliance on iron, potentially sparing healthy tissue due to differing iron management.","Findings link Telomir-1's effect to Jumonji domain histone demethylases (KDM5A/B, KDM6B) involved in cancer aggression and therapy resistance.","Company plans to expand studies to pancreatic and leukemia models, and conduct animal studies ahead of IND submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128023,"accession_number":"0001493152-25-017072","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir-1 restores MASPIN and RASSF1A tumor suppressors in prostate cancer models","event_type":"other_material","confidence":"high","bullets":["Telomir-1 reversed DNA hypermethylation to reactivate MASPIN and RASSF1A in aggressive prostate cancer models.","MASPIN is a natural defense protein blocking invasion and promoting chemotherapy sensitivity; RASSF1A regulates cell cycle and metastasis suppression.","Dose-dependent reduction in RASSF1A methylation; stronger effect when combined with chemotherapy.","Company continues IND-enabling studies for Telomir-1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144810,"accession_number":"0001493152-25-013970","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir-1 inhibits KDM5 demethylase families in vitro, expanding epigenetic targeting","event_type":"other_material","confidence":"medium","bullets":["Telomir-1 inhibits KDM5A, KDM5B, and KDM5C in vitro, blocking silencing of tumor suppressor genes.","Adds to prior activity on KDM2/KDM6 families and DNA methylation, unique among epigenetic therapies.","Telomir-1 spared GCN5L2 acetyltransferase, indicating potential for reduced systemic toxicity.","IND-enabling studies and GMP scale-up ongoing; additional preclinical evaluations in cancer and aging."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144809,"accession_number":"0001641172-25-026931","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir reports preclinical data: Telomir-1 reactivates CDKN2A, beats rapamycin and chemo","event_type":"other_material","confidence":"high","bullets":["New data in PC3 human prostate cancer xenografts shows Telomir-1 inhibits DNA hypermethylation of CDKN2A.","Telomir-1 outperformed rapamycin and chemotherapy in reactivating the master tumor suppressor CDKN2A.","Findings build on prior STAT1 data, supporting Telomir-1 as a broad-spectrum DNA methylation reset therapy.","Company advancing pre-IND program with CMC and IND-enabling studies toward first IND submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144808,"accession_number":"0001641172-25-026527","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharmaceuticals raises $2.9M via block sale of 1.55M shares at $1.87/share","event_type":"other_material","confidence":"high","bullets":["Sold 1,550,000 shares of common stock to institutional investors at $1.87 average price.","Gross proceeds of approximately $2.9 million, before fees and expenses.","Price represented a premium to the prior day's closing price.","Transaction executed via the StockBlock platform through Rodman & Renshaw; no warrants issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144807,"accession_number":"0001641172-25-025688","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir reports in vitro data: Telomir-1 inhibits UTX and modestly targets Tankyrases","event_type":"other_material","confidence":"high","bullets":["Telomir-1 potently inhibits UTX (KDM6A), a histone demethylase linked to cancer, aging, neurodegeneration.","Low-level inhibition of Tankyrases (PARP5A/B) may disrupt Wnt/β-catenin pathway without telomere shortening risks.","Selectivity vs GCN5L2 suggests cleaner safety margin vs other epigenetic drugs.","Prior in vivo data showed reactivation of tumor suppressors STAT1/TMS1 and telomere elongation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144806,"accession_number":"0001641172-25-022506","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes","event_type":"other_material","confidence":"high","bullets":["Telomir-1 inhibited JMJD3, FBXL10, and FBXL11 histone demethylase enzymes in a Eurofins Discovery study.","Overactivation of these enzymes silences tumor suppressors and activates pro-inflammatory and metabolic genes.","Telomir-1 may restore normal gene expression, supporting development in cancer, autoimmune, neurodegeneration, and metabolic disorders.","Data builds on prior results showing Telomir-1 reversed epigenetic silencing of STAT1 and TMS1 in PC3 prostate cancer xenograft models.","Company is preparing to advance Telomir-1 into IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144805,"accession_number":"0001641172-25-020687","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharmaceuticals reports Telomir-1 restores mitochondrial function without cell division in Progeria study","event_type":"other_material","confidence":"high","bullets":["Telomir-1 increased mitochondrial energy (WST-1 assay) and reduced ROS under basal and stress conditions.","No increase in live cell number was observed, confirming no stimulation of cell proliferation.","Activity was greater in Progeria fibroblasts than in healthy cells, suggesting disease-selective effects.","Results may inform development in Parkinson's, ALS, Alzheimer's, Werner's, and Progeria.","IND-enabling studies for Telomir-1 are ongoing; clinical path evaluation continues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144804,"accession_number":"0001641172-25-020563","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharmaceuticals sells 1.1M shares in block sales, raises ~$2.9M","event_type":"other_material","confidence":"high","bullets":["Sold 1,100,000 shares at avg price $2.6045 (premium to prior close) to institutional investors.","Gross proceeds ~$2.9M; trades facilitated via Rodman & Renshaw on StockBlock platform.","No warrants issued; offering conducted through existing ATM equity facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144803,"accession_number":"0001641172-25-020042","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir-1 reverses STAT1 epigenetic silencing in prostate cancer, outperforming Paclitaxel and Rapamycin","event_type":"other_material","confidence":"high","bullets":["In PC3 xenograft model, Telomir-1 fully reversed STAT1 hypermethylation after 21-day oral daily dosing.","No STAT1 reversal was seen with Paclitaxel; only partial demethylation was observed with Rapamycin.","Telomir-1 also reduced TMS1 hypermethylation, a pro-apoptotic tumor suppressor involved in immune signaling.","Telomere length in tumor tissue was not elongated, addressing a key safety concern for telomere-targeting compounds.","Company is advancing Telomir-1 toward IND filing and evaluating it in Wilson's disease, AMD, autism, and dysphonia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163217,"accession_number":"0001641172-25-015522","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharmaceuticals announces positive preclinical data for Telomir-1 in progeria cell lines","event_type":"other_material","confidence":"high","bullets":["Telomir-1 significantly increased cell viability in human HGPS cells under basal and metal-toxic conditions.","Telomir-1 normalized reactive oxygen species (ROS) levels in Progeria cells, reducing oxidative stress.","Telomir-1 reversed calcium overload, restoring mitochondrial function and energy balance.","Company is finalizing IND-enabling studies and plans to engage FDA for orphan drug designation.","Data builds on prior Telomir-1 results in Werner syndrome models (zebrafish, C. elegans) showing lifespan extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163216,"accession_number":"0001641172-25-014648","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir-1 shows dose-dependent reversal of Wilson's disease symptoms in animal model","event_type":"other_material","confidence":"high","bullets":["Up to 4-5x reduction in episodic tremor events; normalization of swim and exploratory behavior.","Approximately 50% reduction in copper accumulation in dry liver tissue.","ALT, AST, bilirubin restored to normal levels, indicating protection of liver function.","Significant improvement in liver and kidney histopathology scores to near-normal.","IND submission planned by year-end; human clinical trials targeted for H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163215,"accession_number":"0001641172-25-013711","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir-1 preclinical study in Werner Syndrome model shows 100% survival, reverses epigenetic aging","event_type":"other_material","confidence":"high","bullets":["Oral Telomir-1 restored healthy DNA methylation at two CpG island regions, resetting the epigenetic clock.","Telomere length increased beyond levels seen in healthy controls.","Full reversal of muscle and body weight loss in the Werner Syndrome animal model.","100% survival in Telomir-1-treated animals vs 15% mortality in untreated controls.","Oxidative stress markers reduced by up to 50%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163214,"accession_number":"0001641172-25-013196","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharmaceuticals announces BIO 2025 participation and preclinical progress for Telomir-1","event_type":"other_material","confidence":"high","bullets":["Telomir will participate in the BIO International Convention 2025 in Boston from June 16-19, 2025, with scheduled partnering meetings.","The company plans to submit an IND by year-end and initiate first-in-human clinical trials in the first half of 2026.","Preclinical data showed retinal regeneration in AMD, lifespan extension in Progeria/Werner's, reversal of Type 2 diabetes parameters, and ~50% tumor reduction in prostate cancer model.","Telomir launched a rare disease initiative targeting Werner's, Wilson's, Progeria, and dysphonia, and introduced Telomir-Ag2 for multidrug-resistant bacteria including MRSA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163213,"accession_number":"0001641172-25-012785","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Telomir Pharmaceuticals reports Telomir-1 restores vision in AMD animal model","event_type":"other_material","confidence":"high","bullets":["Telomir-1 improved central vision response and motion detection in AMD zebrafish model.","Retinal layer regeneration observed: INL, GCL, IPL, OPL thickness increased.","Reactive oxygen species reduced ~50% vs. untreated; 15% mortality in controls vs. 0% in treated.","Results support continued advancement toward IND submission."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163212,"accession_number":"0001641172-25-011938","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["1.01","5.02","3.02","9.01"],"status":"ready","headline":"Telomir Pharmaceuticals appoints Alan Weichselbaum as CFO; prior CFO Michelle Yanez departs","event_type":"leadership","confidence":"high","bullets":["Michelle Yanez and Telomir mutually agreed to her resignation as CFO, Treasurer, Secretary effective May 16, 2025; no disagreement.","Alan Weichselbaum appointed CFO starting May 19, 2025; part-time role (30 hrs/week), salary $60,000/year.","Weichselbaum receives 50,000 stock options vesting over 12 months (25k at 6 months, 25k at 12 months).","Weichselbaum concurrently serves as CFO of MIRA Pharmaceuticals and CEO of Wexus Group.","Employment is at-will, remote from New York, subject to background/reference check."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163211,"accession_number":"0001641172-25-011868","cik":1971532,"company_name":"Telomir Pharmaceuticals, Inc.","ticker":"TELO","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Telomir Pharmaceuticals raises $3M via premium equity sale from largest shareholder","event_type":"other_material","confidence":"high","bullets":["$3 million raised via direct investment by Bayshore Trust (largest shareholder) at $3.00/share, 18% premium to $2.54 close.","1 million restricted shares issued; no warrants, no discounts, no convertible features.","Proceeds to fund Telomir-1 IND submission for a rare disease indication.","Follows prior $1M investment at $7.00/share and complements $5M undrawn line of credit from same group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}